Micreos, a Netherlands-based endolysin technology developer backed by cigarette producer Altria, raised €32m ($37.5m) in funding from undisclosed investors yesterday.
Founded in 2005, Micreos is working on technology utilising endolysins – hydrolytic enzymes that can attack specific unwanted bacteria while leaving the remainder of the microbiome intact and thus present an advantage over antibiotics.
The technology was developed with university ETH Zurich, and Micreos will use the money to accelerate the development of its lead assets targeting atopic dermatitis, diabetic wounds and bloodstream infections.
Altria Ventures, the investment arm of cigarette producer Altria, acquired a 5% stake in the company in 2012 in return for an undisclosed amount of funding. Micreos subsequently secured $13.3m from unnamed backers in 2016.
The original version of this article appeared on our sister site, Global University Venturing.
